Aurinia Pharmaceuticals (NASDAQ:AUPH) reported Q2 EPS of ($0.25), $0.03 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $28.2 million versus the...
Pre-Open Stock Movers: Snap (NYSE:SNAP) 33% LOWER; reported Q2 EPS of ($0.02), versus the analyst estimate of ($0.20). Revenue for the quarter came in at $1.11 billion versus the...
Aurinia Pharmaceuticals (NASDAQ:AUPH) AUPH shares rallied 6.6% in the last trading session to close at $29.84. This move can be attributable to notable volume with a higher number...
Investors in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) need to pay close attention to the stock based on moves in the options market lately. That is because the Mar 20, 2020 $16...
1. Aurinia Pharmaceuticals AUPH was up 70 cents, or 3.74%, to 19.44, after reaching a high of 19.53, on 1.5 million shares on Tuesday, and may be coming out of a flag that...
Aurinia Pharmaceuticals Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases. The Company has developed LUPKYNISTM, for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory advancement to support the voclosporin development program. LUPKYNIS is a calcineurin inhibitor (CNI) immunosuppressant, that improves near and long-term outcomes in LN when used in combination with mycophenolate mofetil and steroids. LUPKYNIS reduces cytokine activation and blocks interleukin IL-2 expression and T-cell mediated immune responses. Voclosporin, the active ingredient in LUPKYNIS, is made by a modification of a single amino acid of the cyclosporine molecule. It also focuses on treatment of autoimmune, fibrotic, and kidney-related diseases. Its product pipeline includes AUR200, AUR300.
|Average||21.31 (+184.51% Upside)|
|No. of Analysts||7|